Sleep is a key indicator of population health, affecting individual quality of life, broader public health, and overall health security. In China, approximately 30%48% of adults experience insomnia, and the prevalence continues to rise [1]. Insomnia may elevate the risk of chronic conditions such as hypertension and diabetes and is associated with anxiety and depression [1], making it a pressing public health concern.
In this installment of PI Talk, MedJ speaks with Academician Lin Lu of the Chinese Academy of Sciences and Prof. Bin Zhang, Director of the Department of Psychiatry and the Sleep Medicine Center at Nanfang Hospital, Southern Medical University. Lu served as principal investigator of the Chinese Phase III clinical trial of lemborexant, an important step in insomnia pharmacotherapy in China. Zhang served as principal investigator of both that Phase III study and PROEM, the first prospective, multicenter, realworld study of lemborexant in China. The two experts discuss epidemiological trends, the evolving treatment paradigm, accumulating Chinese evidence on DORA drugs, and future directions for sleep medicine.
Expert Profile: Academician Lin Lu
- l Boya Chair Professor, Peking University; Director, National Center for Medical Diseases of Mental Disorders; Director, National Clinical Research Center for Mental and Psychological Diseases; President, Shandong First Medical University
- l Principal Investigator, National Natural Science Foundation of China Basic Science Center and Innovative Research Group
- l Has long been engaged in research on the pathogenesis and intervention strategies of mental, psychological, and sleep disorders
- l Proposed new models for intervening in pathological memory and identified new targets for rapid antidepressant action
- l Has published more than 400 SCI papers in journals including Science, Lancet, Lancet Public Health, Lancet Psychiatry, and JAMA Psychiatry
- l Recipient of numerous awards including the National Innovation Award, Outstanding Overseas Chinese Individual, the T.H. Tan Life Science Achievement Award, the Ho Leung Ho Lee Foundation Science and Technology Progress Award, First Prize of the Ministry of Education Higher Education Outstanding Scientific Research Achievement Award (Natural Science), First and Second Prizes of the Chinese Medical Science and Technology Award, Second Prize of the National Natural Science Award, and the Beijing Science and Technology Progress Award
Expert Profile: Prof. Bin Zhang
- l Chief Physician, Doctoral Supervisor, and Postdoctoral CoSupervisor; Director, Department of Psychiatry and the Sleep Medicine Center, Nanfang Hospital, Southern Medical University; Vice Director, Brain Disease Research Institute, Nanfang Hospital
- l Chief Scientist of a 14th FiveYear National Key Research and Development Program project; EditorinChief of the national planning textbook Sleep Medicine
- l Listed among the World’s Top 2% Scientists in 2023
- l Vice Chairman, Chinese Sleep Research Society, and Chair of its Sleep Medicine Education Committee
- l Standing Committee Member, Sleep Medicine Committee, Chinese Medical Doctor Association; Vice Chair, Sleep Branch, China Association for International Exchange of Medical Care
- l Member, Chinese Medical Association Psychiatry Branch; Member, Chinese Medical Doctor Association Psychiatry Branch; Chair, Guangdong Medical Doctor Association Sleep Medicine Committee; Vice Chair, Guangdong Medical Doctor Association Psychiatry Branch
- l Has led National Key R\&D Program projects and National Natural Science Foundation of China grants
- l EditorinChief or coeditor of more than 10 monographs, including Sleep Medicine and the Chinese Guidelines for the Diagnosis and Treatment of Insomnia Disorder; has published more than 160 papers
The Current Landscape and Unmet Needs in Insomnia Care
MedJ: Academician Lin Lu, as a leading figure in Chinese psychiatry, how would you characterize the current epidemiological trends of insomnia in China? What shifts in treatment philosophy have you seen in recent years, and what new challenges do they pose for clinical practice?
Academician Lin Lu: Up to 48% of the general population in China is affected by insomnia, and the prevalence of insomnia disorder ranges from 16% to 21% [1]. The patient population is becoming younger, a trend closely tied to work stress and lifestyle factors. Sleep is foundational to health, and scientific research indicates that sleep is closely related to hypertension, diabetes, and even mental disorders [1]. In real life, many younger adults neglect sleep, with irregular schedules and late nights, while many older adults experience insomnia or unstable sleep, manifesting as difficulty initiating sleep, difficulty maintaining sleep, or earlymorning awakening.
The evolution of treatment philosophy has been driven by these changing clinical needs. Rather than focusing solely on extending sleep duration, the field has shifted toward improving daytime functioning and quality of life during wakefulness [1]. Treatment goals should balance reducing daytime impairment and avoiding the negative effects of pharmacotherapy [1]. As a result, new clinical challenges have emerged: from sleep health literacy, to quantifying daytime mental state, cognitive function, and emotional stability, to individualizing treatment plans.
MedJ: Prof. Bin Zhang, you served as PI of the Chinese Phase III trial of lemborexant and are the lead investigator of the PROEM study, the first prospective, multicenter, realworld study of lemborexant in China. What are the characteristics of Chinese insomnia patients and the current clinical landscape?
Prof. Bin Zhang: From a clinical perspective, Chinese patients with insomnia have a wide age range and a complex medication history, and clinical care often lacks specialist input. Patients present across multiple specialties, including general practice and neurology, and prescribing practices vary in quality. More importantly, insomnia rarely occurs in isolation: approximately 70%80% of patients with mental disorders report insomnia symptoms [1], which further complicates treatment decisions.
In realworld settings, clinicians commonly see patients who have already tried multiple medications or have complex comorbidities, and treatment decisions in these cases are more complex than in clinical trials. Lemborexant’s efficacy and safety have been confirmed in registration studies, yet systematic data on its use across diverse and complex patient populations in Chinese realworld practice are still lacking. This gap motivated the launch of the PROEM study.
DORA Evidence in China: From Study Design to Clinical Findings
MedJ: We have discussed the current landscape and challenges. DORA agents have accumulated substantial clinical data in China. What local considerations were incorporated into the study design to address the clinical characteristics of Chinese insomnia patients?
Academician Lin Lu: DORA drugs launched in China last year have been studied in rigorous randomized, doubleblind, controlled trials. Consistent with global research, these trials have shown efficacy in Chinese insomnia patients. Phase III studies, using objective indicators such as polysomnography (PSG), have shown that DORA drugs can facilitate sleep onset, increase sleep duration, and are generally well tolerated [2].
The local adaptation was reflected in the patient population: Chinese participants had a mean age of 42.7 years, considerably younger than the 63.9 years in the global SUNRISE 1 study [3]. This design choice aligns with the younger demographic profile of insomnia in China. It is also clinically meaningful because younger patients often place higher demands on nextday cognitive performance. Traditional benzodiazepine receptor agonists (BZRAs) can produce nextday drowsiness and dizziness [4], whereas current evidence suggests that DORA drugs are relatively safe, with no significant residual sedative effects, low dependence risk, and limited impact on nextday functioning [2].
MedJ: With rigorous quality control, what sleep dimensions have DORA drugs primarily improved, from a data standpoint, and what are the practical implications for patients’ daytime function and overall quality of life?
Academician Lin Lu: DORAs represent a new class of sedativehypnotic agents with established clinical efficacy and distinctive advantages. The class can effectively shorten sleep latency, extend total sleep time, reduce nighttime awakening frequency and duration, and significantly improve core insomnia symptoms such as difficulty initiating and maintaining sleep, while improving sleep efficiency. In efficacy terms, DORAs shorten sleep latency by approximately 35 minutes after the first dose and by nearly 40 minutes after one month of treatment; wake time after sleep onset is significantly reduced, total sleep time is extended by 61 minutes, and sleep efficiency is improved by 13% [2].
These improvements translate into practical gains for patients: more complete nighttime sleep architecture, supporting restored daytime energy, attention, and emotional stability, and reduced daytime sleepiness. In addition, clinical studies suggest that DORA drugs may effectively improve anxiety and depressive symptoms that often accompany insomnia. Clinical trials are also underway to explore their effects in patients with mild dementia and comorbid insomnia, with the potential to improve cognitive function and possibly delay neurodegenerative progression.
MedJ: PROEM is the first prospective, multicenter, realworld study of lemborexant in China. It enrolled treatmentnaive monotherapy patients, patients switching from traditional hypnotics, and patients receiving combination therapy. How do the benefits differ across these treatment modalities?
Prof. Bin Zhang: PROEM enrolled 200 patients. Of these, 37.5% were also receiving BZRAs, 22.0% nonbenzodiazepine agents, while initial monotherapy accounted for 21.0%, switching for 16.5%, and combination therapy for 62.5% [5]. Overall, the cohort had a long disease course, severe symptoms, and a complex medication background.
After four weeks of treatment, the initial monotherapy group showed an insomnia remission rate (Insomnia Severity Index, ISI < 8) of 54.1% and a response rate (ISI reduction ≥ 6 points) of 78.4% [5], both significantly higher than those in the switching and combination groups. These findings suggest that in Chinese realworld settings, treatmentnaive patients should be prioritized for lemborexant monotherapy. The switching group showed a 6.86point decrease in ISI from baseline at week 4, and the combination group a 6.56point decrease [5]; both reductions were also significant. The data suggest that patients with prior treatment failure or longterm hypnotic use can still benefit from lemborexant, and that previous hypnotics can be successfully transitioned to lemborexant. Overall, initial monotherapy produced the largest benefit, while switching and combination regimens may provide feasible bridging strategies for patients with inadequate response or dependence on traditional hypnotics.
MedJ: PROEM observed reductions in anxiety and depression scores after lemborexant treatment, along with important findings on switching and tapering. How do you view lemborexant’s value for mood improvement and withdrawal management? What is the safety profile observed?
Prof. Bin Zhang: PROEM showed that PHQ9 (Patient Health Questionnaire9) and GAD7 (Generalized Anxiety Disorder7) scores declined significantly by week 1 of lemborexant treatment and remained lower through week 4 (P < 0.001) [5], suggesting that lemborexant may have positive effects on comorbid mood symptoms while improving insomnia. On safety, lemborexant showed consistent efficacy across age groups and was well tolerated. Adverse events were mostly mild to moderate; common reactions such as somnolence and nightmares typically appeared within the first 20 days of treatment and resolved spontaneously after about one to two weeks [5]. Patient expectation management is important in clinical use.
On withdrawal management, PROEM provided key evidence: 90.9% of switching patients successfully discontinued their previous hypnotics within four weeks [5], and BZRAequivalent doses also decreased significantly in combinationtherapy patients. Two strategies can be adopted accordingly: direct switching may be appropriate for patients with good adherence and manageable withdrawal symptoms, while stepwise tapering may suit patients on high doses or with prior failed withdrawals. Because lemborexant and BZRAs have different mechanisms, a slow transition is recommended when switching, reducing the previous dose by onequarter every two weeks [4], to improve tolerability.
Future Directions for Sleep Medicine in China
MedJ: From an international perspective, what important trends do you see in global sleep medicine? Looking ahead 510 years, what is your outlook for the discipline and strategic direction of sleep medicine in China?
Academician Lin Lu: Global sleep medicine is moving toward greater precision and individualization. Good sleep is fundamental to work efficiency, quality of life, and wellbeing, while insomnia not only increases the risk of workplace errors but, when chronic, is associated with multiple comorbidities and adds to the overall disease burden. It would be valuable for every hospital of sufficient scale to establish a dedicated sleep clinic, helping insomnia patients recover and reducing the medical burden driven by chronic insomnia and its comorbidities.
Looking ahead 510 years, four priorities stand out:
First, strengthen systemic capacity. Expand specialist training, promote standardized guidelines, and direct them into primary care to build an institutional foundation for sleep medicine.
Second, strengthen public education. Encourage regular schedules and appropriate exercise as ways to protect sleep health and raise sleephealth literacy across the population.
Third, expand treatment options. Beyond pharmacotherapy, integrate physical therapies and lifestyle interventions into a diversified, comprehensive care system.
Fourth, deepen basic and clinical research. Develop safer sleep agents without dependence risk, accumulate evidence in Chinese populations, and explore the potential of DORA drugs in improving cognition and modulating neurodegenerative changes.
The future requires continued integration of basic research, clinical evidence, and expert consensus, along with strengthened primarycare training to promote appropriate use and comprehensive patient recovery.
MedJ: How do you view the positioning and value of DORA drugs such as lemborexant in the longterm standardized treatment of insomnia? What unmet needs in longterm insomnia management deserve further exploration?
Prof. Bin Zhang: DORA drugs have a distinctive role in longterm, standardized insomnia treatment. Their mechanism of action differs from traditional gammaaminobutyric acid (GABA) drugs, offering a new therapeutic approach with very low addiction risk, making them particularly suitable for chronic insomnia patients requiring longterm therapy.
Unmet needs in longterm insomnia management include:
First, although comprehensive treatment is recommended, the integration pathways between pharmacotherapy and cognitivebehavioral therapy, physical therapy, and traditional Chinese medicine remain unclear.
Second, evidence on efficacy maintenance and dose adjustment during longterm use is limited; most existing data are shortterm.
Third, insomnia frequently cooccurs with somatic and mental disorders, and the optimal dosing, safety profile, and target population for DORA drugs in comorbid settings still require further postmarketing evidence.
From Academician Lin Lu’s macro perspective on epidemiological trends and treatment philosophy evolution to Prof. Bin Zhang’s detailed interpretation of the PROEM findings, this installment of PI Talk offers a comprehensive review of lemborexant’s Chinese evidence pathway, from study design to realworld data. The limitations of traditional sedativehypnotics are being surpassed by agents with new mechanisms, and Chinese insomnia care is moving toward a more precise, safer era that more closely approximates physiologic sleep regulation.
References
[1] Chinese Sleep Research Society. Guidelines for the diagnosis and treatment of insomnia (2025 edition). Chinese Medical Journal. 2025;105(34):29602981.
[2] Mi WF, Wen D, Xu L, et al. A phase 3, multicenter, doubleblind, randomized, placebocontrolled clinical trial of lemborexant in adults with insomnia disorder. Sleep Med. 2026;139:108722.
[3] Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254.
[4] Chinese Medical Association Neurology Branch, Sleep Disorders Group. Chinese guidelines for the diagnosis and treatment of adult insomnia (2023 edition). Chinese Journal of Neurology. 2023;57(6):560584.
[5] Zheng S, Li X, Jian W, et al. Patientreported outcomes for lemborexant treatment in Chinese patients with insomnia (PROEM): a multicenter, prospective, realworld observational study. Nat Sci Sleep. 2026;18:5